GlassScriptPhysician profile
Frank D Miller
NPI 1770553067
$1,701.64
in general payments reported to CMS, 2019-2025
21 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.78 · 2020: $35.98 · 2021: $71.14 · 2022: $73.06 · 2023: $95.89 · 2024: $798 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.18 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $181.90 | 2019-2024 | |
| Abbvie INC. | $163.70 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.33 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $94.25 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.78 | 2024 | |
| Shield Therapeutics INC | $79.15 | 2024 | |
| Lilly USA, LLC | $75.80 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $72.44 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.05 | 2024-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $60.34 | 2024-2025 | Fanapt |
| Amgen INC. | $38.97 | 2024 | Otezla, Repatha |
| Novo Nordisk INC | $38.11 | 2024-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $34.58 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $29.91 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.65 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $21.99 | 2021 | |
| Glaxosmithkline, LLC. | $19.88 | 2025 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $15.78 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.96 | 2025 | Caplyta |
| Astellas Pharma US INC | $13.89 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.